Search results
Boosting CAR-T cell therapies from under the skin
Medical Xpress· 7 days agoOncological researchers suspect that disappointing treatment results can be the result of several circumstances, including poor quality of the CAR-T cell
Secondary Tumors After CAR-T Cancer Therapies Are Rare: Study
WFMZ Eastern Pennsylvania and Western New Jersey· 6 days agoCAR-T cell therapy to treat blood cancers is safer than previously thought, with little risk that...
APAC leaps ahead in adoptive cell therapy space
Clinical Trials Arena via Yahoo Finance· 2 days agoHe also highlighted that overall, there are 1,023 single country adoptive cell therapy clinical studies being run in the APAC region compared to 476 in...
Finding The Right Balance Of T Cell Expansion And Phenotype For Cell Therapy
BioresearchOnline· 3 days agoExplore this study that works to determine the optimal concentrations of IL-7 and IL-15 for T cell...
FDA official: The risk of secondary cancer from CAR-T therapy is less than feared
Medical Xpress· 2 days agoThe risk of secondary cancer after CAR-T therapy, pioneered at Penn, is less than regulators feared...
Kyverna's CAR-T relapse in lupus dents autoimmune hopes amid biotech gold rush
FierceBiotech· 2 days agoThe “remarkable” success of chimeric antigen receptor T-cell therapy (CAR-T) in lupus has led to a...
Immunotherapy to treat cancer gave rise to 2nd cancer in extremely rare case
Live Science via Yahoo News· 6 days agoNew research provides insight into ultra-rare case of secondary cancer in a patient who received CAR...
Train Eyes so Myopia Doesn't Get Worse? Nurse Intervention for BP Post-Stroke
MedPage Today· 4 days agoTTHealthWatch is a weekly podcast from Texas Tech. This week's topics include eye training to...
CARsgen’s CAR T MM therapy shows early signs of efficacy in Phase I trial
Clinical Trials Arena via Yahoo Finance· 2 days agoT cell therapy accounts for 55% of all adoptive cell therapy trials, according to data obtained ...
Why Is Mustang Bio (MBIO) Stock Up 347% Today?
InvestorPlace· 2 days agoThe recent news includes favorable results from the company’s Phase 1/2 clinical trial of MB-106. This is a CD20-targeted, autologous CAR T-cell
